Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 4:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 176 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Sitagliptin Clear all
Completed Phase 2 Interventional Results available

Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes

NCT01338870
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, 25 mg PF-04991532, 75 mg PF-04991532, 150 mg PF-04991532, 300 mg PF-04991532, Sitagliptin 100 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
25
States / cities
Little Rock, Arkansas • Roseville, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Jun 7, 2026, 4:41 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

NCT03115112
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Bexagliflozin, Sitagliptin, Placebo for sitagliptin, Placebo for bexagliflozin
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Lincoln, California • Long Beach, California • San Dimas, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Jun 7, 2026, 4:41 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus

NCT00760344
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
SYR-472, Placebo, Sitagliptin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
105
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 102 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Jun 7, 2026, 4:41 AM EDT
Terminated Phase 3 Interventional Results available

TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes

NCT01829464
View directory record Official record
Conditions
Diabetes
Interventions
Placebo, TAK-875
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
82
States / cities
Birmingham, Alabama • Dothan, Alabama • Muscle Shoals, Alabama + 78 more
Source: ClinicalTrials.gov public record
Updated May 31, 2016 · Synced Jun 7, 2026, 4:41 AM EDT
Completed Phase 4 Interventional Results available

Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy

NCT01859793
View directory record Official record
Conditions
Diabetes, Atherosclerosis
Interventions
sitagliptin, Placebo
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
21 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 20, 2016 · Synced Jun 7, 2026, 4:41 AM EDT
Completed Phase 4 Interventional Results available

Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant

NCT01928199
View directory record Official record
Conditions
Posttransplant Diabetes Mellitus
Interventions
Sitagliptin, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Jun 7, 2026, 4:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin

NCT02956044
View directory record Official record
Conditions
Type2 Diabetes Mellitus
Interventions
Bexagliflozin, Metformin, Glimepiride, Sitagliptin
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Jun 7, 2026, 4:41 AM EDT
Completed Phase 3 Interventional Results available

The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)

NCT01137812
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Sitagliptin 100 mg, Canagliflozin 300 mg, Metformin, Sulphonylurea
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
85
States / cities
Mobile, Alabama • Goodyear, Arizona • Mesa, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2015 · Synced Jun 7, 2026, 4:41 AM EDT
Completed No phase listed Observational

Replication of the GRADE Diabetes Trial in Healthcare Claims Data

NCT05099198
View directory record Official record
Conditions
Diabetes
Interventions
Sitagliptin, Glimepiride
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
30 Years and older
Enrollment
6,403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Jun 7, 2026, 4:41 AM EDT
Completed Phase 4 Interventional Results available

Sitagliptin in Combination With Metformin and Sulfonylurea

NCT00686634
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sitagliptin
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Jun 7, 2026, 4:41 AM EDT
Completed Phase 3 Interventional Results available

The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)

NCT01106690
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Canagliflozin, Sitagliptin, Metformin, Pioglitazone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
41
States / cities
Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2013 · Synced Jun 7, 2026, 4:41 AM EDT
Completed Phase 3 Interventional Results available

24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years

NCT00976937
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Lixisenatide (AVE0010), Lixisenatide Placebo, Pen auto-injector, Sitagliptin, Sitagliptin Placebo, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 49 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
21
States / cities
Montgomery, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Jun 7, 2026, 4:41 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes

NCT02607865
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, sitagliptin, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
93
States / cities
Anniston, Alabama • Birmingham, Alabama • Tuscumbia, Alabama + 81 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Jun 7, 2026, 4:41 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.

NCT07567781
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-722, Midazolam, Metformin, Digoxin, Pitavastatin, Sitagliptin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 7, 2026, 4:41 AM EDT
Completed Phase 2 Interventional Results available

12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin

NCT02647320
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sitagliptin 100 mg, DS-8500a 25mg, Placebo Tablet, Placebo Capsule
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 70 Years
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
48
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Tempe, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2019 · Synced Jun 7, 2026, 4:41 AM EDT
Completed Phase 3 Interventional Results available

Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin

NCT01046110
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, sitagliptin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
57
States / cities
Huntsville, Alabama • Concord, California • Fresno, California + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jun 7, 2026, 4:41 AM EDT
Completed Phase 3 Interventional Results available

Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus

NCT01652729
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Exenatide once weekly suspension, Sitagliptin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
60
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Jun 7, 2026, 4:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals

NCT00813228
View directory record Official record
Conditions
Diabetes Mellitus Type 1, Diabetes Mellitus Type 2
Interventions
Sitagliptin (Januvia)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Jun 7, 2026, 4:41 AM EDT
Completed No phase listed Observational Results available

A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents

NCT01077323
View directory record Official record
Conditions
Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies), Healthy Subjects (Treated With no Diabetes Therapies)
Interventions
exenatide, Other antidiabetic therapies, No diabetes therapy
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
Not listed
Enrollment
363,766 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Jun 7, 2026, 4:41 AM EDT
Completed No phase listed Observational

Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control

NCT00806520
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2015 · Synced Jun 7, 2026, 4:41 AM EDT
Terminated Phase 4 Interventional Results available

Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery

NCT01970462
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hyperglycemia
Interventions
Sitagliptin, Placebo
Drug
Lead sponsor
Kathleen Dungan
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 17, 2018 · Synced Jun 7, 2026, 4:41 AM EDT
Terminated Phase 3 Interventional

Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone

NCT01089790
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dutogliptin, Sitagliptin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 86 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
149
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 121 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Jun 7, 2026, 4:41 AM EDT
Completed Phase 4 Interventional Results available

Effect of DPP4 Inhibition on Vasoconstriction

NCT02639637
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sitagliptin, Placebo, Neuropeptide Y, Enalaprilat, Valsartan 160mg
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 26, 2018 · Synced Jun 7, 2026, 4:41 AM EDT
Completed No phase listed Observational

Emulation of the SUSTAIN6 Diabetes Trial Using Healthcare Claims

NCT06659744
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
New use of semaglutide injection, New initiation of sitagliptin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
158,310 participants
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jun 7, 2026, 4:41 AM EDT